Singh Ramanpreet, Makary Mina S
Northeast Ohio Medical University, Rootstown, OH, 44272, USA.
Division of Vascular and Interventional Radiology, Department of Radiology, The Ohio State University Medical Center, Columbus, OH, 43210, USA.
J Gastrointest Cancer. 2025 Jul 23;56(1):162. doi: 10.1007/s12029-025-01280-2.
Portal vein tumor thrombus (PVTT) develops in up to half of patients with hepatocellular carcinoma (HCC) and historically signifies advanced-stage disease with limited treatment options and poor prognosis. Systemic therapy has been the standard treatment for HCC with PVTT, but this review highlights the potential of image-guided locoregional therapies including transarterial chemoembolization (TACE), transarterial embolization (TAE) radioembolization (TARE), hepatic arterial infusion chemotherapy (HAIC), and ablative or radiotherapeutic approaches to improve outcomes in this challenging context. We will summarize current evidence and clinical experience demonstrating that these modalities can achieve meaningful tumor control and extend survival, especially when tailored to tumor burden and PVTT extent or combined with systemic treatments. These findings underscore that aggressive locoregional treatment can be a valuable component of multidisciplinary management for advanced HCC, offering select patients an improved prognosis despite PVTT.
门静脉肿瘤血栓(PVTT)在多达一半的肝细胞癌(HCC)患者中出现,从历史上看,它意味着疾病处于晚期,治疗选择有限且预后较差。全身治疗一直是伴有PVTT的HCC的标准治疗方法,但本综述强调了影像引导下局部区域治疗的潜力,包括经动脉化疗栓塞(TACE)、经动脉栓塞(TAE)、放射性栓塞(TARE)、肝动脉灌注化疗(HAIC)以及消融或放射治疗方法,以在这一具有挑战性的情况下改善治疗效果。我们将总结当前的证据和临床经验,证明这些治疗方式能够实现有意义的肿瘤控制并延长生存期,特别是在根据肿瘤负荷和PVTT范围进行调整或与全身治疗相结合时。这些发现强调,积极的局部区域治疗可以成为晚期HCC多学科管理的重要组成部分,为部分患者提供改善的预后,尽管存在PVTT。